Monday, October 24, 2011

Pancreatic Cancer

According to American Cancer Society, more than 44,000 new cases of pancreatic cancer will be giagnosed in the U.S. and over 37,000 deaths are expected in 2011.

Approved Drugs:

Single agent:
Gemzar [gemcitabine] : Eli Lilly (LLY), single agent, approved  in1997 for locally advanced or metastatic panreatic exocrine cancer. Median OS: 5.7 months, one-year probability of survival rate: 18%.

Combination agents:
Gemzar [gemcitabine] plus Tarceva [erlotinib] from Roche/Astellas Parma, the only successful combination approved by the FDA in 2005. Median OS: 6.4 months, one-year survival rate: 23%.

From: 13 Drug Companies Trying to Beat the Odds in Pancreatic Cancer